Isaac Singini1, Thomas B Campbell2, Laura M Smeaton3, Nagalingeswaran Kumarasamy4, Alberto La Rosa5, Sineenart Taejareonkul6, Steven A Safren7, Timothy P Flanigan8, James G Hakim9, Michael D Hughes3. 1. a Johns Hopkins Research Project , Blantyre , Malawi. 2. b Department of Medicine/Division of Infectious Diseases , University of Colorado School of Medicine , Aurora , CO , USA. 3. c Center for Biostatistics in AIDS Research , Harvard T.H. Chan School of Public Health , Boston , MA , USA. 4. d Chennai Antiviral Research and Treatment (CART) CRS , YRGCARE Medical Centre , Chennai , India. 5. e Therapeutic Research , Asociacion Civil Impacta Salud y Educacion , Lima , Peru. 6. f Research Institute for Health Sciences , Chiang Mai University , Chiang Mai , Thailand. 7. g Department of Psychology , University of Miami , Miami , FL , USA. 8. h Miriam Hospital, Brown University , Providence , RI , USA. 9. i University of Zimbabwe College of Health Sciences , Harare , Zimbabwe.
Abstract
BACKGROUND: Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression. METHODS: Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ≥1000 copies/mL after 24 weeks). RESULTS: During median follow-up of 3.5 years, 82/911 participants (9%) experienced late VF. Of 516 participants reporting missed doses during the first 24 weeks of ART, 55 (11%) experienced late VF, compared with 27 (7%) of 395 participants reporting no missed doses (hazard ratio: 1.73; 95% CI: 1.08, 2.73). This difference persisted in multivariable analysis, in which lower pre-ART hemoglobin and absence of Grade ≥3 laboratory results prior to week 24 were also associated with higher risk of late VF. DISCUSSION: In this clinical trial, the late VF rate after successful suppression was very low. If achievable in routine clinical practice, virologic monitoring involving infrequent (e.g. annual) measurements might be considered; the implications of this for development of resistance need evaluating. Patients reporting missed doses early after ART initiation, despite achieving initial suppression, might require more frequent measurement and/or strategies for promoting adherence.
BACKGROUND: Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression. METHODS:Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ≥1000 copies/mL after 24 weeks). RESULTS: During median follow-up of 3.5 years, 82/911 participants (9%) experienced late VF. Of 516 participants reporting missed doses during the first 24 weeks of ART, 55 (11%) experienced late VF, compared with 27 (7%) of 395 participants reporting no missed doses (hazard ratio: 1.73; 95% CI: 1.08, 2.73). This difference persisted in multivariable analysis, in which lower pre-ART hemoglobin and absence of Grade ≥3 laboratory results prior to week 24 were also associated with higher risk of late VF. DISCUSSION: In this clinical trial, the late VF rate after successful suppression was very low. If achievable in routine clinical practice, virologic monitoring involving infrequent (e.g. annual) measurements might be considered; the implications of this for development of resistance need evaluating. Patients reporting missed doses early after ART initiation, despite achieving initial suppression, might require more frequent measurement and/or strategies for promoting adherence.
Authors: A Cozzi-Lepri; A N Phillips; B Clotet; J Kjaer; V Von Wyl; G Kronborg; A Castagna; J R Bogner; J D Lundgren Journal: HIV Med Date: 2011-08-17 Impact factor: 3.180
Authors: Michael Abouyannis; Joris Menten; Agnes Kiragga; Lutgarde Lynen; Gavin Robertson; Barbara Castelnuovo; Yukari C Manabe; Steven J Reynolds; Lesley Roberts Journal: AIDS Date: 2011-08-24 Impact factor: 4.177
Authors: Roos E Barth; Susan C Aitken; Hugo Tempelman; Sibyl P Geelen; Erik M van Bussel; Andy I M Hoepelman; Rob Schuurman; Annemarie M J Wensing Journal: Antivir Ther Date: 2011-12-02
Authors: Matthew P Fox; Gilles Van Cutsem; Janet Giddy; Mhairi Maskew; Olivia Keiser; Hans Prozesky; Robin Wood; Miguel A Hernán; Jonathan A C Sterne; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731
Authors: Thomas B Campbell; Laura M Smeaton; N Kumarasamy; Timothy Flanigan; Karin L Klingman; Cynthia Firnhaber; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Umesh Lalloo; Cynthia Riviere; Jorge Sanchez; Marineide Melo; Khuanchai Supparatpinyo; Srikanth Tripathy; Ana I Martinez; Apsara Nair; Ann Walawander; Laura Moran; Yun Chen; Wendy Snowden; James F Rooney; Jonathan Uy; Robert T Schooley; Victor De Gruttola; James Gita Hakim Journal: PLoS Med Date: 2012-08-14 Impact factor: 11.069
Authors: Zahra Reynolds; Suzanne M McCluskey; Mahomed Yunus S Moosa; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin L Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Pravi Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent A Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi; Mwebesa Bosco Bwana; Mark J Siedner Journal: HIV Med Date: 2021-11-09 Impact factor: 3.094